LB Phar­ma­ceu­ti­cals rais­ing $75M for schiz­o­phre­nia drug as Karuna looks to change the field

As Karuna Ther­a­peu­tics wraps up its FDA ap­proval re­quest for what could be the first new type of schiz­o­phre­nia drug in decades, an­oth­er East Coast biotech is rais­ing $75 mil­lion to test an ad­just­ed ver­sion of a decades-old med­i­cine for the dis­or­der next year.

LB Phar­ma­ceu­ti­cals has se­cured about $35 mil­lion so far and ex­pects an­oth­er $40 mil­lion in the round, ac­cord­ing to an SEC fil­ing on Thurs­day. Per the fi­nan­cial doc­u­ment, its board in­cludes di­rec­tors as­so­ci­at­ed with Vi­da Ven­tures, Pon­tif­ax, Deep Track Cap­i­tal and TCGX, a crossover firm that has in­vest­ed in mul­ti­ple nine-fig­ure biotech fi­nanc­ings in re­cent months, in­clud­ing Car­mot Ther­a­peu­tics, Alkeus and Up­stream Bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER